Septerna Appoints Veteran Biotechnology Leader Keith Gottesdiener, M.D., to its Board of Directors
Septerna (NASDAQ: SEPN), a clinical-stage biotech company focused on G protein-coupled receptor (GPCR) drug discovery, has appointed Dr. Keith Gottesdiener to its Board of Directors. Dr. Gottesdiener, who brings over 30 years of experience in advancing medicines, will chair the newly formed R&D Committee.
Dr. Gottesdiener's extensive background includes serving as CEO of Prime Medicine and Rhythm Pharmaceuticals, where he led the development and approval of setmelanotide. At Merck Research Laboratories, he oversaw the approval of more than 20 novel therapeutics and over 200 successful IND submissions as Worldwide Head of Late-Stage Development.
Septerna (NASDAQ: SEPN), una società biotecnologica in fase clinica focalizzata sulla scoperta di farmaci per i recettori GPCR, ha nominato Dr. Keith Gottesdiener nel suo Consiglio di Amministrazione. Il Dott. Gottesdiener, che vanta oltre 30 anni di esperienza nel portare avanti i farmaci, presiederà il nuovo Comitato di Ricerca e Sviluppo (R&D).
Il prezioso bagaglio di esperienza del Dott. Gottesdiener comprende ruoli di CEO di Prime Medicine e Rhythm Pharmaceuticals, dove ha guidato lo sviluppo e l'approvazione di setmelanotide. Presso Merck Research Laboratories, ha supervisionato l'approvazione di più di 20 nuove terapie e oltre 200 submission IND di successo come Worldwide Head of Late-Stage Development.
Septerna (NASDAQ: SEPN), una empresa biotecnológica en fase clínica centrada en el descubrimiento de fármacos GPCR, ha nombrado al Dr. Keith Gottesdiener a su Junta Directiva. El Dr. Gottesdiener, que aporta más de 30 años de experiencia en avanzar medicamentos, presidirá el recientemente formado Comité de I+D.
La amplia trayectoria del Dr. Gottesdiener incluye haber sido CEO de Prime Medicine y Rhythm Pharmaceuticals, donde lideró el desarrollo y la aprobación de setmelanotide. En Merck Research Laboratories, supervisó la aprobación de más de 20 terapias nuevas y más de 200 presentaciones IND exitosas como Worldwide Head of Late-Stage Development.
Septerna (NASDAQ: SEPN), GPCR 표적 약물 발견에 중점을 둔 임상 단계 생명공학 회사가 이사회를 Keith Gottesdiener 박사를 임명했습니다. Gottesdiener 박사는 약 30년이 넘는 의약품 개발 경험을 바탕으로 새로 구성된 연구개발위원회를 이끌 것입니다.
Gottesdiener 박사의 광범위한 경력에는 Prime Medicine와 Rhythm Pharmaceuticals의 CEO로서 세트멜라노타이드의 개발 및 승인을 이끈 경험이 포함됩니다. Merck Research Laboratories에서 Worldwide Head of Late-Stage Development로서 신약 20종 이상의 승인을 감독했고 200건이 넘는 IND 제출의 성공을 이끌었습니다.
Septerna (NASDAQ: SEPN), une société biotechnologique en phase clinique axée sur la découverte de médicaments ciblant les récepteurs GPCR, a nommé Dr. Keith Gottesdiener à son conseil d'administration. Le Dr Gottesdiener, qui apporte plus de 30 ans d'expérience dans l'avancement des médicaments, présidera le nouveau Comité R&D.
Le riche parcours du Dr Gottesdiener comprend des postes de PDG de Prime Medicine et Rhythm Pharmaceuticals, où il a dirigé le développement et l'approbation du setmelanotide. Chez Merck Research Laboratories, il a supervisé l'approbation de plus de 20 thérapies nouvelles et plus de 200 soumissions IND réussies en tant que Worldwide Head of Late-Stage Development.
Septerna (NASDAQ: SEPN), ein biotechnologisches Unternehmen in klinischer Phase, das sich auf die Entdeckung von Medikamenten für GPCR-Neuigkeiten konzentriert, hat Dr. Keith Gottesdiener in den Vorstand berufen. Dr. Gottesdiener bringt über 30 Jahre Erfahrung in der Arzneimittelentwicklung mit und wird den neu gegründeten F&E-Ausschuss leiten.
Gottesdieners umfangreicher Hintergrund umfasst seine Rolle als CEO von Prime Medicine und Rhythm Pharmaceuticals, wo er die Entwicklung und Zulassung von Setmelanotide leitete. Bei Merck Research Laboratories beaufsichtigte er die Zulassung von mehr als 20 neuartigen Therapeutika und über 200 erfolgreichen IND-Einreichungen als Worldwide Head of Late-Stage Development.
Septerna (NASDAQ: SEPN)، شركة تكنولوجيا حيوية في مرحلتها السريرية تركز على اكتشاف أدوية مستقبلات GPCR، عيّنت الدكتور كيث غوتسدنير في مجلس إدارتها. يجلب الدكتور غوتسدنير أكثر من 30 عامًا من الخبرة في تطوير الأدوية، وسيترأس لجنة البحث والتطوير التي تم تشكيلها حديثًا.
تشمل الخلفية الواسعة للدكتور غوتسدنير عمله رئيسًا تنفيذيًا لشركتي Prime Medicine و Rhythm Pharmaceuticals، حيث قاد تطوير والموافقة على Setmelanotide. في Merck Research Laboratories، أشرف على موافقة أكثر من 20 علاجًا جديدًا و أكثر من 200 تقديم IND ناجح بصفته Worldwide Head of Late-Stage Development.
Septerna (NASDAQ: SEPN)，一家处于临床阶段、专注于GPCR受体药物发现的生物技术公司，任命Keith Gottesdiener 博士加入其董事会。Gottesdiener 博士在推进药物方面拥有超过30年的经验，将担任新成立的研发委员会主席。
Gottesdiener 博士的广泛背景包括担任 Prime Medicine 与 Rhythm Pharmaceuticals 的首席执行官，在那里他领导了 setmelanotide 的开发与批准。在默克研究实验室，他作为 Worldwide Head of Late-Stage Development，监管了超过20种新药的批准以及超过200次成功的IND提交。
- Appointment of highly experienced executive with over 30 years in drug development
- Addition of leader with track record of multiple drug approvals and 200+ IND submissions
- Strengthening of R&D oversight with new dedicated board committee
- None.
SOUTH SAN FRANCISCO, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (NASDAQ: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced the appointment of Keith Gottesdiener, M.D., to its board of directors. A seasoned biotechnology executive with over 30 years of experience advancing medicines from discovery through commercialization, Dr. Gottesdiener will serve as chairperson of a newly constituted R&D Committee of the Board.
“Dr. Gottesdiener’s exceptional track record of successfully advancing novel therapeutics from discovery through development to approval, combined with his deep expertise in regulatory strategy and clinical development across multiple therapeutic areas, will be invaluable as we advance our lead programs and build Septerna into a premier GPCR therapeutics company,” said Jeffrey Finer, M.D., Ph.D., Chief Executive Officer and Co-founder of Septerna. “His appointment comes at a pivotal time as we advance our lead programs and continue building our pipeline of potential differentiated GPCR-targeted therapies.”
“Septerna has established a truly differentiated approach to GPCR drug discovery through its proprietary Native Complex Platform™, creating significant opportunities to address unmet medical needs across multiple therapeutic areas,” said Dr. Gottesdiener. “The company’s innovative science and strong clinical pipeline, including the promising PTH1R program for hypoparathyroidism, position Septerna well to deliver meaningful therapies for patients. I look forward to working with the talented team to help guide the company’s continued growth and development.”
Dr. Gottesdiener has held leadership roles spanning academia, pharmaceutical R&D, and public biotechnology companies. He most recently served as President and Chief Executive Officer of Prime Medicine, Inc., leading the gene-editing company through IPO. Prior to that, Dr. Gottesdiener served as Chief Executive Officer of Rhythm Pharmaceuticals, Inc., where he oversaw the development and approval of setmelanotide for three indications in rare genetic forms of obesity. Before joining the biotechnology industry, Dr. Gottesdiener spent 16 years at Merck Research Laboratories, where he served as Worldwide Head of Late-Stage Development and Worldwide Head of Early Development, with major program responsibilities for the approval of more than 20 novel therapeutics and over 200 successful IND submissions. Earlier in his career, he was Associate Professor of Medicine at Columbia University College of Physicians and Surgeons. Dr. Gottesdiener previously served on the board of directors of Intercept Pharmaceuticals, Inc. He received his M.D. from the University of Pennsylvania Medical School and his A.B. in Applied Mathematics from Harvard University.
About Septerna
Septerna, Inc. is a clinical-stage biotechnology company with a world-class team of GPCR experts and drug developers advancing cutting-edge science to unlock the full potential of GPCR therapies for patients with significant unmet needs. The company’s proprietary Native Complex Platform™ is designed to enable new approaches to GPCR drug discovery and has led to the development of a diverse pipeline of novel oral small molecule drug candidates. Septerna is advancing programs in endocrinology, immunology and inflammation, metabolic diseases and additional therapeutic areas, both independently and with partners. For more information, please visit www.septerna.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements about Septerna’s beliefs and expectations regarding: the continued development and advancement of its oral small molecule GPCR-targeted programs; its ability to demonstrate, and the timing of, preclinical proof-of-concept in vivo and ex vivo studies for multiple programs; its ability to continue to advance product candidates that it may identify and successfully complete clinical studies; the potential of its proprietary Native Complex Platform™; its expectations regarding the implementation of its business model, strategic plans for its business, product candidates, and technology. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “objective,” “ongoing,” “plan,” “predict,” “project,” “potential,” “should,” or “would,” or the negative of these terms, or other comparable terminology are intended to identify forward-looking statements, although not all forward looking statements contain these identifying words.
Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks associated with: uncertainties related to the results of preclinical studies, or clinical studies not being predictive of future results in connection with future studies; Septerna’s product candidates entering into and successfully advancing through clinical trials; the authorization, initiation, and successful completion of preclinical and Investigational New Drug (IND)-enabling studies to support future clinical development of potential product candidates (including those for the PTH1R program), including uncertainties related to opening INDs and obtaining regulatory approvals; risks related to clinical development outcomes including unexpected safety or efficacy findings; the scope of protection Septerna is able to establish and maintain for intellectual property rights covering its Native Complex Platform™ and its product candidates; Septerna’s ability to identify and enter into future license agreements and collaborations; and general economic, industry and market conditions. These and other risks and uncertainties are described in greater detail in the section entitled “Risk Factors” in Septerna’s Annual Report on Form 10-K for the year ended December 31, 2024, as well as any subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent Septerna’s views only as of today and should not be relied upon as representing its views as of any subsequent date. Septerna explicitly disclaims any obligation to update any forward-looking statements subject to any obligations under applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.
Investor Contact:
Renee Leck, THRUST
renee@thrustsc.com
Media Contact:
Carly Scaduto, THRUST
carly@thrustsc.com
FAQ
Who is Keith Gottesdiener and what is his new role at Septerna (NASDAQ: SEPN)?
What is Dr. Gottesdiener's experience in the biotech industry?
What is Septerna's (SEPN) main focus as a company?
What are the key programs Septerna (SEPN) is currently developing?
